Trevena Inc. (NASDAQ:TRVN) was down 2.5% during mid-day trading on Thursday . The company traded as low as $6.85 and last traded at $6.90, with a volume of 278,128 shares. The stock had previously closed at $7.08.

A number of equities research analysts have issued reports on TRVN shares. TheStreet downgraded shares of Trevena from a “hold” rating to a “sell” rating in a research note on Friday, June 17th. Cowen and Company reissued a “buy” rating and issued a $13.00 target price on shares of Trevena in a report on Friday, August 5th. Zacks Investment Research raised shares of Trevena from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. Brean Capital reissued a “buy” rating and issued a $14.00 target price on shares of Trevena in a report on Friday, August 5th. Finally, FBR & Co reissued a “buy” rating and issued a $13.00 target price on shares of Trevena in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. Trevena has an average rating of “Buy” and an average target price of $14.30.

The stock has a 50-day moving average of $6.84 and a 200-day moving average of $7.48. The stock’s market capitalization is $367.33 million.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.01. Equities research analysts forecast that Trevena Inc. will post ($1.55) earnings per share for the current year.

A number of hedge funds and institutional investors recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in Trevena during the fourth quarter worth $1,929,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Trevena by 15.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 216,705 shares of the biopharmaceutical company’s stock worth $2,275,000 after buying an additional 29,300 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Trevena by 0.3% in the fourth quarter. Jennison Associates LLC now owns 702,341 shares of the biopharmaceutical company’s stock worth $7,375,000 after buying an additional 2,341 shares during the last quarter.

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.